Rudolfstiftung Hospital, Vienna, Austria (Prof G Schernthaner MD) Correspondence to: Prof Guntram Schernthaner, Rudolfstiftung Hospital, A-1030 Vienna, Austriaguntram.schernthaner@meduniwien.ac.atExenatide once weekly versus liraglutide once daily in  patients with type 2 diabetes (DURATION-6): a randomised, open-label study John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao,  Marilyn K Boardman, Mark Fineman, Lisa Porter, Guntram Schernthaner Summary Background Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve  glycaemic control and reduce bodyweight in patients with type 2 diabetes. We compared the eï¬ƒ    cacy and safety of  exenatide once weekly with liraglutide once daily in patients with type 2 diabetes. Methods We did a 26 week, open-label, randomised, parallel-group study at 105 sites in 19 countries between Jan 11,